hVIVO (OPORF) FFO


OPORF hVIVO PLC OPORF
43 GF Score
Price $0.11
GF Value $0.60
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is hVIVO FFO?

FFO (Funds from operations) only applies to REITs.

OPORF
43GF Score
hVIVO PLC OPORF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is hVIVO (OPORF) Overvalued in 2026?

Based on GuruFocus' analysis, hVIVO stock appears to be undervalued. The current stock price of $0.11 is trading 81.7% below its estimated GF Value™ of $0.60. GuruFocus considers hVIVO to be Possible Value Trap.

Key valuation signals for OPORF:

  • FFO:
  • GF Value™: $0.60 vs. price of $0.11 (81.7% below fair value)
  • GF Score™: 43/100 with 6 warning signs

No single metric tells the full story. See the OPORF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

hVIVO Business Description

Other Exchanges HVO:UKCRO:Germany
Address 40 Bank Street, Floor 24, London, GBR, E14 5NR
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
43GF Score

Get the complete analysis for OPORF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.60
GF Value